Quattro Financial Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Quattro Financial Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-5,000	Closed	-$486K	–	85
2023 Q1	$486K	Sell	5,000 -5,000	-50%	-$518K	0.2%	61
2022 Q4	$1.03M	Hold	10,000	–	–	0.41%	39
2022 Q3	$848K	Hold	10,000	–	–	0.34%	45
2022 Q2	$829K	Sell	10,000 -2,000	-17%	-$159K	0.28%	48
2022 Q1	$925K	Hold	12,000	–	–	0.31%	52
2021 Q4	$1.06M	Hold	12,000	–	–	0.37%	55
2021 Q3	$901K	Hold	12,000	–	–	0.24%	64
2021 Q2	$954K	Hold	12,000	–	–	0.25%	62
2021 Q1	$958K	Buy	+12,000	New	+$980K	0.22%	68

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Quattro Financial Advisors's BMRN Position: Q2 2023 in Review

Quattro Financial Advisors sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2023, closing a stake of 5,000 shares — an estimated $486K sold.

Quattro Financial Advisors first reported a position in BMRN in Q1 2021 and held it in 9 quarters. The position peaked at $1.06M in Q4 2021. 558 funds tracked by Wall St. Rank hold BMRN as of Q2 2023.

Quattro Financial Advisors reported no remaining BioMarin Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Quattro Financial Advisors sold 5,000 BioMarin Pharmaceuticals shares in Q2 2023, an estimated $486K.
Quattro Financial Advisors first reported a position in BioMarin Pharmaceuticals in Q1 2021 and held it in 9 quarters.
Quattro Financial Advisors's BioMarin Pharmaceuticals position peaked at $1.06M in Q4 2021.
558 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2023.

Based on Quattro Financial Advisors's 13F filing for Q2 2023, filed 25 Jul 2023.